Small dense LDL-6 (sdLDL-6) represents one of the smallest and most pathogenic LDL particle subfractions measured in advanced lipid testing. At this level of particle density and size, atherogenic properties are near their maximum — these particles penetrate the arterial intima with exceptional ease, resist LDL receptor-mediated clearance, and undergo oxidative modification rapidly after arterial wall entry.
The presence of elevated sdLDL-6 alongside sdLDL-5 and sdLDL-7 defines the most severe form of small dense LDL dyslipidaemia, closely associated with very advanced metabolic dysfunction. sdLDL-6 is part of the integrated total sdLDL assessment that captures cumulative atherogenic particle burden.
FAQs
Is sdLDL-6 more dangerous than sdLDL-1?
Yes. Atherogenicity increases progressively as LDL particles become smaller and denser. sdLDL-6 is far more atherogenic than sdLDL-1, with greater capacity for arterial wall penetration, oxidation, and resistance to clearance.
Who should be tested for sdLDL-6?
People with metabolic syndrome, type 2 diabetes, very high triglycerides, or unexplained cardiovascular disease despite apparently normal standard lipids benefit most from complete sdLDL subfraction analysis.
Can diet specifically reduce sdLDL-6?
Yes. A very low carbohydrate diet dramatically reduces VLDL production and the downstream remodelling cascade that generates small dense particles including sdLDL-6. This is one of the strongest arguments for carbohydrate restriction in people with atherogenic dyslipidaemia.
Is sdLDL-6 tested separately or as part of a panel?
sdLDL-6 is part of the complete small dense LDL subfraction panel, not ordered in isolation. The full panel provides a comprehensive picture of the atherogenic particle burden.
